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ABSTRACT Glucocorticoids are well-established an-
ti-inflammatory drugs thought to mainly act by inhibi-
tion of proinflammatory transcription factors like NF-
B. In recent years, however, transcription factor-
independent mechanisms of glucocorticoid action have
been proposed, namely the influence on MAPK path-
ways. Here we identify MAPK phosphatase-1 (MKP-1)
as a pivotal mediator of the anti-inflammatory action of
glucocorticoids in the human endothelium. We applied
dexamethasone (Dex) to TNF--activated human endo-
thelial cells and used the adhesion molecule E-selectin
as inflammatory read-out parameter. Dex is known to
reduce the expression of E-selectin, which is largely
regulated by NF-B. Here, we communicate that Dex at
low concentrations (1–100 nM) markedly attenuates
E-selectin expression without affecting NF-B. Impor-
tantly, Dex is able to increase the expression of MKP-1,
which causes an inactivation of TNF--induced p38
MAPK and mediates inhibition of E-selectin expres-
sion. In endothelial MKP-1/ cells differentiated
from MKP-1/ embryonic stem cells and in MKP-1-
silenced human endothelial cells, Dex did not inhibit
TNF--evoked E-selectin expression. Thus, our find-
ings introduce MKP-1 as a novel and crucial mediator
of the anti-inflammatory action of glucocorticoids at
low concentrations in the human endothelium and
highlight MKP-1 as an important and promising anti-
inflammatory drug target.—Fu¨rst, R., Schroeder, T.,
Eilken, H. M., Bubik, M. F., Kiemer, A. K., Stefan
Zahler, S., Vollmar, A. M. MAPK phosphatase-1 repre-
sents a novel anti-inflammatory target of glucocorti-
coids in the human endothelium FASEB J. 21, 74–80
(2007)
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Glucocorticoids, such as cortisol, are endogenous
agents produced by the adrenal gland. Glucocorticoids
are essential for normal development and exert influ-
ence on various metabolic and immune defense pro-
cesses. Synthetic glucocorticoids, like dexamethasone
(Dex), are well established and widely used immuno-
suppressive and anti-inflammatory drugs. Glucocorti-
coids have been proven to exert beneficial effects in
different autoimmune diseases and in a plethora of
disorders with an inflammatory component, e.g.,
chronic allergic diseases, asthma, rheumatoid arthritis,
Crohn’s disease, or chronic ulcerative colitis.
Glucocorticoids act by binding to their intracellular
glucocorticoid receptor. Subsequent to its ligand-de-
pendent activation, the receptor translocates to the
nucleus and acts 1) as a transcription factor upon
binding to glucocorticoid response elements of distinct
gene promotors or 2) as a direct inhibitor of proinflam-
matory transcription factors like NF-B, a protein-
protein interaction known as transrepression (1). Met-
abolic effects of glucocorticoids, representing most of
the adverse effects of glucocorticoid therapy, are
mainly ascribed to the transcriptional activity of the
glucocorticoid receptor, whereas the therapeutically
favored anti-inflammatory actions are thought to be
predominantly caused by the mechanism of transre-
pression (2). Recently, a new concept of “non-transcrip-
tional” anti-inflammatory actions of glucocorticoids
emerged: the activated glucocorticoid receptor initiates
a signaling cascade without a direct action on gene
transcription (3).
In the last decades, the endothelium has been rec-
ognized as a fundamental component of the vascular
system. Besides its important function of regulating
blood pressure and coagulation, the endothelium has
been shown to play a crucial role in the inflammatory
response (4). Leukocyte adhesion is known to be of
great importance in this response. In inflammatory
events, endogenous proinflammatory agents, like
TNF-, activate the resting endothelium and lead to an
increased expression of endothelial cell adhesion mol-
ecules, which are responsible for the adhesion of
leukocytes to the endothelium, resulting in leukocyte
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infiltration of inflamed tissue. Since we were interested
in effects of Dex on inflammatory processes in the
human endothelium, we used TNF--activated human
umbilical vein endothelial cell (HUVEC) as a model of
endothelial inflammation. To judge the anti-inflamma-
tory effects of Dex, E-selectin, an important endothelial
adhesion molecule (5), was chosen as inflammatory
read-out parameter.
The involvement of kinases, such as MAPK, in the
regulation of inflammatory processes has been intensively
studied. The role of phosphatases, however, has as yet
been very poorly investigated. Interestingly, recent reports
show that MAPK phosphatases are important for the
control of innate immune response processes (6, 7). We
hypothesized that MAPK phosphatases could represent
important targets for the novel “nontranscriptional” anti-
inflammatory actions of glucocorticoids in endothelial
cells. Moreover, we assumed that investigations into these
mechanisms could lead to the identification of novel
anti-inflammatory drug targets, aiming to improve anti-




Cells were prepared by digestion of umbilical veins with 0.1
g/l collagenase A (Roche, Mannheim, Germany) as described
previously (8) and cultured in endothelial cell growth me-
dium (Promocell, Heidelberg, Germany) containing 10%
FCS (Biochrom, Berlin, Germany). Cells were routinely tested
for mycoplasma contamination with the polymerase chain
reaction (PCR) detection kit VenorGeM (Minerva Biolabs,
Berlin, Germany). Cells were used at passage 3. Before
treatment, confluent cells were starved overnight in a steroid-
free medium consisting of phenol red-free Dulbecco’s mod-
ified Eagle’s medium (DMEM; Bio-Whittaker, Walkersville,
MD) supplemented with 20% charcoal-stripped FCS.
Embryonic stem cell culture and differentiation
Mouse MAPK phosphatase-1 (MKP-1)/ embryonic stem
(ES) cells (9) were kindly provided by the Bristol-Myers
Squibb Pharmaceutical Research Institute (Princeton, NJ,
USA). ES cells were thawed on mouse embryonic feeder cells
and cultured in DMEM (Invitrogen, Carlsbad, CA, USA)
containing 15% FBS (PAN Biotech, Aidenbach, Germany), 20
mM HEPES (Invitrogen), 1 MEM nonessential amino acids
(Invitrogen), 0.1 mM -mercaptoethanol (Invitrogen), and
1,500 U/ml leukemia inhibitory factor (LIF; Chemicon, Te-
mecula, CA, USA). To remove feeder cells, ES cells were
passaged for 2 wk on gelatin-coated dishes. Feeder cell-free
MKP-1/ and D3 ES cells (10) were cultivated in medium
containing Glasgow MEM (Invitrogen), 10% FBS, 1 Na-
pyruvate (Sigma-Aldrich, St. Louis, MO), 1 MEM nonessen-
tial amino acids, 0.05 mM -mercaptoethanol, and 1,000
U/ml LIF. OP9 stroma cells (11) were cultured in -MEM
(Invitrogen) and 20% FBS. For ES cell differentiation, D3 and
MKP-1/ ES cells were cocultured with OP9 cells in differ-
entiation medium (-MEM, 10% FBS, and 0.1 mM -mercap-
toethanol); 72,000 D3 and MKP-1/ cells were seeded on a
60 cm2 dish containing confluent OP9 cells and incubated for
4 d before dissociation with Hank’s enzyme-free dissociation
buffer (Invitrogen). Cells were stained with a monoclonal
allophycocyanin-linked anti-FLK1 antibody (Ab; ref 12) and
propidium iodide (PI, Sigma-Aldrich). FLKPI mesodermal
cells were sorted with FACSAria (Becton Dickinson). After
sorting, viable cells were counted and 31,000 D3 and MKP-
1/ cells were seeded in each well of a type IV collagen-
coated 24-well plate (Becton-Dickinson, Franklin Lakes, NJ),
respectively, and cultured in differentiation medium supple-
mented with 50 ng/ml vascular endothelial growth factor
(VEGF; Sigma-Aldrich) for 4 days.
Determination of MKP-1 and (phospho-)p38 MAPK protein
levels by Western blot analysis
Unless otherwise noted, HUVEC were treated with dexameth-
asone (Calbiochem) (1 nM, 60 min), TNF- (Calbiochem,
San Diego, CA, USA; 10 ng/ml, 15 min), SB203580 (Calbio-
chem; 10 M, 60 min), RU486 (Calbiochem; 10 nM, 15 min),
and sodium vanadate (Na3VO4; 100 M, 30 min). Western
blot analysis was performed as described previously (13).
Antibodies used were as follows: rabbit polyclonal anti-MKP-1
(Santa Cruz Biotechnology, Santa Cruz, CA), antiphospho-
p38 MAPK (Thr180/Tyr182; Cell Signaling), antip38 MAPK
(Cell Signaling, Danvers, MA, USA), and horseradish perox-
idase-conjugated goat anti-rabbit (Dianova, Hamburg, Ger-
many). The Kodak 1D 3.5.4 software (Eastman Kodak, Stutt-
gart, Germany) was used for densitometric analysis.
Analysis of NF-B p65 translocation by
immunocytochemistry and confocal laser
scanning microscopy
HUVEC were cultured on collagen (Biochrom)-coated glass
cover slips, pretreated with dexamethasone (60 min) and
treated with TNF- (10 ng/ml, 30 min), fixed with 4%
buffered formaldehyde (Sigma-Aldrich), permeabilized with
0.2% Triton X-100 (Sigma-Aldrich), and incubated with rab-
bit polyclonal anti-NF-B p65 Ab (Santa Cruz) and Alexa
Fluor 488-linked goat anti-rabbit Ab (Molecular Probes, Eu-
gene, OR). A Zeiss LSM 510 Meta confocal lascer scanning
microscope was used. For quantification of nucleic NF-B p65
levels, the Scion Image software alpha 4.0.3.2 (Scion Corp,
Frederick, MD, USA) was used.
Analysis of NF-B DNA-binding activity by EMSA
HUVEC were treated with dexamethasone (60 min), pyrroli-
dine dithiocarbamate (50 M, 60 min), parthenolide (5 M,
60 min), and TNF- (10 ng/ml, 60 min). Nuclear protein
extracts were prepared, and electrophoretic mobility shift
assays were performed as described previously (13). Bands
were visualized by the Cyclone Storage Phosphor System
(Canberra-Packard, Dreieich, Germany).
Determination of MKP-1 mRNA levels by quantitative
reverse transcriptase-PCR
Total mRNA was extracted with the RNeasy mini kit (Qiagen,
Hilden, Germany) and M-MuLV reverse transcriptase (New
England BioLabs, Beverly, MA) was used. Real-time PCR was
performed with AmpliTaq Gold (Roche). Human MKP-1
primers (biomers.net, Ulm, Germany): 5-GACGCTC-
CTCTCTCAGTCCAA-3 (forward); 5-GGCGCTTTTCGAG-
GAAAAG-3 (reverse); 5-TTCGGCGCAGAGAGACCCGG-3
(probe). Results were quantified based on the relative expres-
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sion of the MKP-1 gene vs. the housekeeping gene GAPDH
using the model of Pfaffl (14).
Analysis of MKP-1 exon 2 integrity by PCR
Genomic DNA was extracted using the DNeasy Tissue Kit (Qia-
gen). PCR was performed with the DyNAmo Probe qPCR Kit
(Finnzymes, Espoo, Finland). Mouse MKP-1 primer (biomers.
net): 5-CAGGTACTGTGTCGGTGGTG-3 (forward); 5-CCT
GGCACAATCCTCCTAGA-3 (reverse). Bands of PCR pro-
ducts were visualized on a Kodak 440cf image station.
MKP-1 antisense experiments
For transfection of human MKP-1 antisense (5-ggtccCGAAT-
GTGCTGagttc-3) and sense phosphorothioate oligonucleo-
tides (biomers.net), jetPEI (Polyplus-Transfection, San Mar-
cos, CA, USA) was used. Further experiments were started
24 h after transfection.
Analysis of E-selectin levels by flow cytometry
Cells were pretreated with dexamethasone (60 min) or
SB203580 (10 M, 60 min), treated with TNF- (10 ng/ml, 4 h),
detached by trypsinization, incubated in 4% buffered formalde-
hyde solution (Sigma-Aldrich), and stained with R-phyco-
erythrin-linked mouse monoclonal anti-human CD62E Ab
(Leinco, St. Louis, MO, USA) or rat monoclonal anti-mouse
CD62E Ab (Abcam, Cambridge, UK) and Alexa Fluor 488-
linked goat antirat Ab (Molecular Probes). Flow cytometric
analysis was performed with FACSCalibur (Becton Dickinson).
Statistical analysis
The number of independently performed experiments is
stated in the respective figure legend. One representative
image is shown. Bar graph data are mean 	 se. Statistical
analysis was performed with the GraphPad Prism software ver-
sion 3.03 (GraphPad Software, San Diego, CA, USA). Unpaired
t test was used to compare two groups. To compare three or
more groups, one-way ANOVA followed by Newman-Keuls post
hoc test was used.
RESULTS
Dex at low concentrations reduces TNF--induced
E-selectin expression and does not influence NF-B
Dex reduces TNF--induced E-selectin expression in
endothelial cells (15). We confirmed this fact in our
Figure 1. Dex at low concentrations readily decreases TNF--induced E-selectin expression and p38 MAPK activity, but does not
influence NF-B. A) Treatment of HUVEC with dexamethasone leads to a concentration-dependent decrease of E-selectin
expression in response to TNF-. A p38 MAPK inhibitor (SB203580) was also able to decrease E-selectin expression on
TNF--treatment. *, P  0.05 vs. untreated control (n
3). B) left panel: TNF- increases amount of NF-B p65 subunit in
nucleus. Dex at low concentrations (1–100 nM) does not influence this effect, whereas a higher Dex concentration (1,000 nM)
decreases the amount of NF-B p65 subunit (n
2). B) right panel: Quantitative analysis of nucleic NF-B p65 content. *P 0.05
vs. untreated control. #P  0.05 vs. only TNF--treated. C) TNF--induced NF-B DNA-binding activity is not affected by Dex
at low concentrations (1–100 nM), whereas a higher Dex concentration (1,000 nM) and the well-known NF-B inhibitors
pyrrolidine dithiocarbamate (PDTC) and parthenolide diminish TNF--evoked NF-B DNA-binding activity (n
4). D)
Treatment with TNF- leads to a phosphorylation (i.e., activation) of p38 MAPK. Dex at a low concentration (1 nM) abrogates
this effect (n
4).
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cell system: pretreatment with Dex concentration de-
pendently reduced the expression of E-selectin (Fig.
1A). Importantly, even low concentrations of Dex (1–
100 nM) lead to a highly significant reduction of
E-selectin expression. The transcription factor NF-B is
thought to play a key role in the up-regulation of
E-selectin on TNF- treatment (16) and Dex is known
to interfere with the NF-B pathway (17). However, we
found that Dex at low concentrations readily decreases
TNF--induced E-selectin expression, whereas it does
not influence TNF--activated NF-B: Dex (1–10 nM)
neither alters the TNF--evoked translocation of the
NF-B p65 subunit (Fig. 1B) nor the increase of NF-B
DNA-binding activity (Fig. 1C). Only high Dex concen-
trations (1,000 nM) were able to abolish the TNF--
induced NF-B activity (Fig. 1C), as did the known
NF-B inhibitors pyrrolidine dithiocarbamate and par-
thenolide. For full activation of TNF--induced E-selec-
tin gene transcription, besides NF-B activation, the
induction of p38 MAPK has been reported to be of
importance (18). Therefore, we treated human endo-
thelial cells with a pharmacological inhibitor of p38
MAPK activity (SB203580), which in fact led to a strong
decrease of E-selectin expression in response to TNF-
(Fig. 1A). Importantly, TNF--evoked p38 MAPK activ-
ity is abrogated by Dex at low concentrations (1 nM;
Fig. 1D), pointing to a crucial role for p38 MAPK in the
up-regulation of E-selectin in our system.
Dex decreases p38 MAPK activity via an induction
of MKP-1
We assumed that Dex could activate a MAPK phospha-
tase, which accounts for the decrease of p38 MAPK
activity. In fact, on treatment of HUVEC with sodium
orthovanadate, an inhibitor of phosphatases, we ob-
served a strongly diminished influence of Dex on
TNF--induced p38 MAPK activity (Fig. 2A), suggesting
that phosphatases are indeed involved. Furthermore,
we hypothesized that MKP-1, the archetypal member of
the family of dual specificity MAPK phosphatases, is
up-regulated by Dex. In fact, we found that Dex con-
centration (Fig. 2B) and time dependently (Fig. 2C)
leads to an increase in endothelial MKP-1 protein
levels. Maximum MKP-1 protein levels were detected
after 60 min treatment with 1 nM Dex. Analysis of
MKP-1 mRNA levels by quantitative RT-PCR showed a
rapid increase of MKP-1 mRNA on Dex treatment
within 5 min (Fig. 2D). Moreover, this up-regulation of
MKP-1 depends on the activation of the glucocorticoid
receptor, as shown be the use of the glucocorticoid
Figure 2. Dex at low concentrations up-regulates endothelial MKP-1 expression. A) left panel: Treatment of HUVEC with Dex
attenuates the TNF--induced phosphorylation (i.e., activation) of p38 MAPK. The phosphatase inhibitor sodium vanadate
(Na3VO4) reverses this effect (n
4). A) right panel: (control experiments): Na3VO4 does neither alter basal nor TNF--induced
p38 MAPK phosphorylation (i.e., activation) (n
3). B) Dex concentration dependently increases expression of MKP-1 protein
(n
7). C) Dex time-dependently increases expression of MKP-1 protein (n
5). D) Dex induces the expression of MKP-1 mRNA
(n
3). E) The glucocorticoid receptor antagonist RU486 is able to block induction of MKP-1 protein by Dex (n
3). *P  0.05
vs. untreated control. #P  0.05 vs. only Dex treated.
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receptor antagonist RU486, which blocked the induc-
tion of MKP-1 protein by Dex (Fig. 2E).
MKP-1 antisense restores p38 MAPK activation and
E-selectin expression
To clarify whether MKP-1 plays a causal role in the
reduction of TNF--induced p38 MAPK activation and
E-selectin expression, we used an MKP-1 antisense
approach. First, we confirmed the functionality of the
applied MKP-1 antisense oligonucleotides: Fig. 3A
shows that transfection of HUVEC with MKP-1 anti-
sense but not sense oligonucleotides abolished cellular
MKP-1 levels increased by Dex. We then treated MKP-
1-silenced endothelial cells with Dex and TNF- and
found that the capability of Dex to diminish the TNF-
-induced activation of p38 MAPK (Fig. 3B) and E-
selectin expression (Fig. 3C) was significantly dimin-
ished. This points to a crucial involvement of MKP-1 in
the deactivation of p38 MAPK and reduction of E-
selectin expression by Dex.
MKP-1 knockout endothelial cells do not react to Dex
treatment
In addition to the antisense approach, we used an
MKP-1 knockout approach. MKP-1/ mouse ES cells
(9) were differentiated into endothelial cells. To con-
firm the lack of MKP-1 gene in ES cells, we checked the
integrity of MKP-1 exon 2: wild-type (WT) ES cells show
an intact exon 2, whereas exon 2 of knockout cells is
disrupted (9; Fig. 4A). In MKP-1 WT endothelial cells,
Dex led to a clear inhibition of E-selectin expression on
TNF- treatment. MKP/ endothelial cells, however,
Figure 3. MKP-1 antisense oligonucleotides block the effect of
Dex on p38 MAPK activity and E-selectin expression. A)
MKP-1 antisense oligonucleotides prevent the induction of
MKP-1 protein by Dex. *P 0.05 vs. only MKP-1 sense treated
(n
3). B) Dex attenuates TNF--induced phosphorylation
(i.e., activation) of p38 MAPK. In MKP-1-silenced (antisense
treated) cells, this ability of Dex is abolished. C) Dex de-
creases the TNF--evoked expression of E-selectin. In MKP-1-
silenced (antisense treated) cells, this effect of Dex is dimin-
ished. *P  0.05 vs. Dex  MKP-1 sense-treatment (n
4).
Figure 4. Effect of Dex on E-selectin expression is prevented
in endothelial MKP-1 knockout cells. A) Embryonic stem cells
from MKP-1 WT and knockout mice were differentiated into
endothelial cells. In knockout cells, exon 2 of MKP-1 gene is
destroyed. WT cells show an intact exon 2. B) Dex leads to a
decrease of E-selectin expression in response to TNF- treat-
ment. In MKP-1 knockout endothelial cells, this effect is
abrogated.
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did not respond to Dex (1 nM): these cells even show a
slight increase of E-selectin expression (Fig. 4B).
DISCUSSION
We found that Dex at very low concentrations (1–100
nM) leads to a highly significant reduction of E-selectin
induced by TNF-. It is commonly accepted that the
up-regulation of E-selectin in activated endothelial cells
is an NF-B-regulated event (16) and that Dex inter-
feres with the NF-B pathway (17). This interference is
thought to be one of the major mechanisms of action of
Dex responsible for its anti-inflammatory properties.
Therefore, it was intriguing to find that Dex at low
concentrations readily decreases TNF--evoked E-selec-
tin expression, whereas it does not influence TNF--
activated NF-B.
Besides the known NF-B-dependent up-regulation
of E-selectin by TNF-, an additional pathway has been
described that occurs in parallel to the NF-B-pathway:
TNF- activates both p38 MAPK and c-Jun NH2-termi-
nal kinase (JNK), resulting in the phosphorylation of
the transcription factors activating transcription fac-
tor-2 (ATF-2) and c-Jun, respectively. The NF-B- and
the ATF-2/c-Jun-pathway converges on the E-selectin
promoter. Both pathways are required for full activa-
tion of E-selectin gene transcription in response to
TNF- (18). Moreover, a study by Reimold et al. stressed
the importance of ATF-2 activation for E-selectin ex-
pression, since ATF-2-deficient mice show an attenu-
ated E-selectin expression (19). These facts highlight
the important role for p38 MAPK in the up-regulation
of E-selectin by TNF-. In accordance with these find-
ings, we found that a pharmacological inhibitor of p38
MAPK activity was able to significantly decrease E-
selectin expression (50% reduction) in HUVEC.
In recent years, an influence of glucocorticoids on
different members of the MAPK family has been in-
creasingly recognized as a novel mechanism involved in
glucocorticoid action (20). In line with this new con-
cept, we found that pretreatment of Dex (1 nM)
abrogates TNF--induced p38 MAPK activity in human
umbilical endothelial cells. A study by Pelaia et al.
reporting that Dex (100 nM) is able to prevent TNF--
induced activation of p38 MAPK in human pulmonary
endothelial cells (21) supports our results. Interest-
ingly, Gonza´lez et al. revealed that TNF--activated p38
MAPK is not influenced by Dex at 1,000 nM in the
human endothelial cell line HMEC-1 (22). These facts
suggest a concentration-dependent effect of Dex on the
activation of p38 MAPK.
The question arose how Dex is able to decrease the
activity of p38 MAPK. Our assumption that a phospha-
tase could account for this decrease was confirmed by
the fact that a phosphatase inhibitor blocked the effect
of Dex on p38 MAPK. We have shown MKP-1 to be
crucially involved in the deactivation of TNF--induced
p38 MAPK in endothelial cells (8, 23). Additionally,
Lasa et al. reported that MKP-1 is the only p38 MAPK-
inhibiting phosphatase induced by Dex in epithelial
cells (24). Therefore, we hypothesized an induction of
MKP-1 by Dex and, in fact, found a time- and concen-
tration-dependent up-regulation of MKP-1. We for the
first time provide evidence that a glucocorticoid is able
to increase MKP-1 protein levels in the human endo-
thelium. Analysis of the MKP-1 mRNA level revealed
that it raises within 5 min, which easily explains the
rapid induction of MKP-1 protein within 15 min. Em-
ploying an inhibitor of the glucocorticoid receptor, we
proved an involvement of this receptor in the induction
of MKP-1 by Dex, which excludes an unspecific effect of
Dex by binding to other subcellular structures than the
glucocorticoid receptor.
It has to be mentioned that in most studies Dex is
used at concentrations of 100 nM, whereas in our
system Dex concentrations as low as 1 nM lead to a
strong up-regulation of MKP-1 and an effective deacti-
vation of p38 MAPK. Interestingly, higher Dex concen-
trations (1,000 nM) do not lead to an induction of
MKP-1 but reduce NF-B activity. This suggests that the
pathways Dex uses for the transduction of its anti-
inflammatory properties depend on the applied con-
centration. It can be speculated that low glucocorticoid
concentrations, which are therapeutically preferred to
limit side effects, exert their anti-inflammatory poten-
tial in endothelial cells rather via induction of MKP-1
than via blockade of NF-B.
An involvement of MKP-1 in the action of glucocor-
ticoids in endothelial cells has as yet been hypothetical
(20). By using an MKP-1 antisense and knockout ap-
proach, we for the first time provide evidence that
Dex-induced MKP-1 plays a pivotal role in the reduc-
tion of p38 MAPK and, most importantly, E-selectin
expression induced by TNF- .
In summary, our study highlights the relevance of
MKP-1 as an important player in inflammatory reac-
tions of the human endothelium. MKP-1 represents a
novel and crucial mediator of the anti-inflammatory
actions of glucocorticoids at low concentrations. The
pathways glucocorticoids use for their anti-inflamma-
tory action obviously depend on the applied glucocor-
ticoid concentration. In conclusion, the present study
points out the importance of studying mechanisms of
action of well-established anti-inflammatory pharma-
ceuticals, since this approach could lead to re-evalua-
tion of anti-inflammatory principles: our data indicate
that MKP-1 represents a promising pharmacological
target for the treatment of inflammatory diseases.
We thank Cornelia Niemann, Silvia Schnegg, and Jana
Peliskova for excellent technical assistance; the Bristol-Myers
Squibb Research Institute for providing mouse embryonic
MKP-1/ stem cells; and the staffs of the “Frauenklinik vom
Roten Kreuz,” “Kreisklinik Mu¨nchen-Pasing,” and “Kru¨s-
mannklinik” for providing umbilical cords.
REFERENCES
1. Leung, D. Y., and Bloom, J. W. (2003) Update on glucocorticoid
action and resistance. J. Allergy Clin. Immunol. 111, 3–22
79Dex INDUCES ENDOTHELIAL MKP-1
2. Scha¨cke, H., Do¨cke, W. D., and Asadullah, K. (2002) Mecha-
nisms involved in the side effects of glucocorticoids. Pharmacol.
Ther. 96, 23–43
3. Limbourg, F. P., and Liao, J. K. (2003) Nontranscriptional
actions of the glucocorticoid receptor. J. Mol. Med. 81, 168–174
4. Galley, H. F., and Webster, N. R. (2004) Physiology of the
endothelium. Br. J. Anaesth. 93, 105–113
5. Ley, K., Allietta, M., Bullard, D. C., and Morgan, S. (1998)
Importance of E-selectin for firm leukocyte adhesion in vivo.
Circ. Res. 83, 287–294
6. Hammer, M., Mages, J., Dietrich, H., Servatius, A., Howells, N.,
Cato, A. C., and Lang, R. (2005) Dual specificity phosphatase 1
(DUSP1) regulates a subset of LPS-induced genes and protects
mice from lethal endotoxin shock. J. Exp. Med. 203, 15–20
7. Zhao, Q., Wang, X., Nelin, L. D., Yao, Y., Matta, R., Manson,
M. E., Baliga, R. S., Meng, X., Smith, C. V., Bauer, J. A., et al.
(2005) MAP kinase phosphatase 1 controls innate immune
responses and suppresses endotoxic shock. J. Exp. Med. 203,
131–140
8. Kiemer, A. K., Weber, N. C., Fu¨rst, R., Bildner, N., Kulhanek-
Heinze, S., and Vollmar, A. M. (2002) Inhibition of p38 MAPK
activation via induction of MKP-1: atrial natriuretic peptide
reduces TNF--induced actin polymerization and endothelial
permeability. Circ. Res. 90, 874–881
9. Dorfman, K., Carrasco, D., Gruda, M., Ryan, C., Lira, S. A., and
Bravo, R. (1996) Disruption of the erp/mkp-1 gene does not
affect mouse development: normal MAP kinase activity in
ERP/MKP-1-deficient fibroblasts. Oncogene 13, 925–931
10. Schroeder, T., Fraser, S. T., Ogawa, M., Nishikawa, S., Oka, C.,
Bornkamm, G. W., Nishikawa, S., Honjo, T., and Just, U. (2003)
Recombination signal sequence-binding protein Jkappa alters
mesodermal cell fate decisions by suppressing cardiomyogen-
esis. Proc. Natl. Acad. Sci. U. S. A. 100, 4018–4023
11. Kodama, H., Nose, M., Niida, S., Nishikawa, S., and Nishikawa,
S. (1994) Involvement of the c-kit receptor in the adhesion of
hematopoietic stem cells to stromal cells. Exp. Hematol. 22,
979–984
12. Kataoka, H., Takakura, N., Nishikawa, S., Tsuchida, K., Kodama,
H., Kunisada, T., Risau, W., Kita, T., and Nishikawa, S. I. (1997)
Expressions of PDGF receptor alpha, c-Kit and Flk1 genes
clustering in mouse chromosome 5 define distinct subsets of
nascent mesodermal cells. Dev. Growth Differ. 39, 729–740
13. Fu¨rst, R., Brueckl, C., Kuebler, W. M., Zahler, S., Kro¨tz, F.,
Go¨rlach, A., Vollmar, A. M., and Kiemer, A. K. (2005) Atrial
natriuretic peptide induces mitogen-activated protein kinase
phosphatase-1 in human endothelial cells via Rac1 and
NAD(P)H oxidase/Nox2-activation. Circ. Res. 96, 43–53
14. Pfaffl, M. W. (2001) A new mathematical model for relative
quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45
15. Brostjan, C., Anrather, J., Csizmadia, V., Natarajan, G., and
Winkler, H. (1997) Glucocorticoids inhibit E-selectin expres-
sion by targeting NF-kappaB and not ATF/c-Jun. J. Immunol.
158, 3836–3844
16. Chen, C. C., and Manning, A. M. (1995) Transcriptional regu-
lation of endothelial cell adhesion molecules: a dominant role
for NF-kappa B. Agents Actions Suppl. 47, 135–141
17. De Bosscher, K., Vanden Berghe, W., and Haegeman, G. (2003)
The interplay between the glucocorticoid receptor and nuclear
factor-kappaB or activator protein-1: molecular mechanisms for
gene repression. Endocr. Rev. 24, 488–522
18. Read, M. A., Whitley, M. Z., Gupta, S., Pierce, J. W., Best, J.,
Davis, R. J., and Collins, T. (1997) Tumor necrosis factor
alpha-induced E-selectin expression is activated by the nuclear
factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-acti-
vated protein kinase pathways. J. Biol. Chem. 272, 2753–2761
19. Reimold, A. M., Grusby, M. J., Kosaras, B., Fries, J. W., Mori, R.,
Maniwa, S., Clauss, I. M., Collins, T., Sidman, R. L., Glimcher, M. J.,
and Glimcher, L. H. (1996) Chondrodysplasia and neurological
abnormalities in ATF-2-deficient mice. Nature 379, 262–265
20. Clark, A. R., and Lasa, M. (2003) Crosstalk between glucocorti-
coids and mitogen-activated protein kinase signalling pathways.
Curr. Opin. Pharmacol. 3, 404–411
21. Pelaia, G., Cuda, G., Vatrella, A., Grembiale, R. D., De Sarro, G.,
Maselli, R., Costanzo, F. S., Avvedimento, V. E., Rotiroti, D., and
Marsico, S. A. (2001) Effects of glucocorticoids on activation of
c-jun N-terminal, extracellular signal-regulated, and p38 MAP
kinases in human pulmonary endothelial cells. Biochem. Pharma-
col. 62, 1719–1724
22. Gonzalez, M. V., Gonzalez-Sancho, J. M., Caelles, C., Munoz, A.,
and Jimenez, B. (1999) Hormone-activated nuclear receptors
inhibit the stimulation of the JNK and ERK signalling pathways
in endothelial cells. FEBS Lett. 459, 272–276
23. Weber, N. C., Blumenthal, S. B., Hartung, T., Vollmar, A. M.,
and Kiemer, A. K. (2003) ANP inhibits TNF-alpha-induced
endothelial MCP-1 expression: involvement of p38 MAPK and
MKP-1. J. Leukoc. Biol. 74, 932–941
24. Lasa, M., Abraham, S. M., Boucheron, C., Saklatvala, J., and
Clark, A. R. (2002) Dexamethasone causes sustained expression
of mitogen-activated protein kinase (MAPK) phosphatase 1 and
phosphatase-mediated inhibition of MAPK p38. Mol. Cell. Biol.
22, 7802–7811
Received for publication June 22, 2006.
Accepted for publication July 31, 2006.
80 Vol. 21 January 2007 FU¨RST ET AL.The FASEB Journal
